Jaguar Health, Inc. (JAGX)
|Net Income (ttm)||-35.30M|
|Trading Day||January 15|
|Day's Range||3.12 - 3.45|
|52-Week Range||0.19 - 4.00|
SAN FRANCISCO, CA / ACCESSWIRE / January 15, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today provided the replay link for the Company's January 14, 2021 investor web...
Regeneron Pharmaceuticals (NASDAQ: REGN) shares are trading higher after the company announced an additional U.S. order to purchase 1.25 million doses of its COVID-19 antibody cocktail bringin...
Jaguar Health Enters Non-dilutive Binding Term Sheet for $6.0 Million Sale of Partial Rights to Possible Tropical Disease Priority Review Voucher
This additional non-dilutive financing will support development program for lechlemer for the indication of the symptomatic relief of diarrhea and dehydration in cholera patients REMINDER: Jag...
Jaguar Health Announces $15 Million Registered Direct Offering Priced Above-the-Market Under Nasdaq Rules
SAN FRANCISCO, CA / ACCESSWIRE / January 13, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced it has entered into a securities purchase agreement with two i...
If you believe in the future of plant-based medical treatments, then a long position in JAGX stock could offer exposure to this technology. The post Don't Try to Tame Jaguar Health Stock As It...
Jaguar Health to Present at the H.C. Wainwright BIOCONNECT 2021 Virtual Conference the Week of January 11th and at 4:30 pm Eastern on Tuesday, January 19th at the NobleCon17 Virtual Conference
REMINDER: Jaguar-hosted investor webcast scheduled for Thursday, January 14 at 11:30 A.M. Eastern Time.
Jaguar Health Exploring Possibility of Conditional Marketing Authorization for Proposed Inflammatory Diarrhea Indication for Crofelemer, Initially in ‘Long-Hauler' COVID-19 Recovery Patients in Europe
New COVID-19 strain estimated to have tripled number of infections in England during November 2020 lockdown Investor webcast scheduled for Thursday, January 14 at 11:30 A.M. Eastern Time.
The developer of plant-based medicines has a promising drug pipeline.
JAGX stock is on the move today as Jaguar Health continues to gain attention. Here's what you should know about the biopharma play now.
Jaguar Health Subsidiary Receiving Preclinical Services from the National Institute of Allergy and Infectious Diseases for New Preclinical Study Initiated January 6, 2021 for Lechlemer Plant-Based Drug Candidate for the Symptomatic Relief of Diarrhea from Cholera
Lechlemer development focused on possible tropical disease priority review voucher SAN FRANCISCO, CA / ACCESSWIRE / January 6, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Compan...
Shares of Jaguar Health Inc., a developer of plant-based medicines for people and animals, soared more than 40% on Tuesday in heavy volume, extending their recent strong gains and putting the ...
JAGX shares are once again on the move this week. Here's what you should know about the maker of the antidiarrheal treatment Mytesi.
JAGX stock is up on news that Jaguar Health just signed a royalty deal that will allow the company to pursue new FDA approvals. The post JAGX Stock: Why Jaguar Health Shares Are Surging 150% T...
This article is going to explain what penny stocks are and discuss four penny stocks under $1 to watch as small-cap stocks continue a hot streak this winter. First thing's first, what are penn...
Cellectar Biosciences (NASDAQ: CLRB) shares are trading lower on Wednesday after the company priced a $24.5 million offering at $1.35 per share. Cellectar Biosciences Inc is a clinical-stage b...
Jaguar Health Signs Second Agreement for $6 Million Non-dilutive Financing Transaction Involving the Sale of Royalty Rights Related to Future Mytesi (Crofelemer) and Lechlemer Revenue Stream
No royalty payments due for 18-24 months Proceeds will be allocated to support regulatory activities associated with the Company's development pipeline, including funding the recently initiate...
Jaguar Health Reports Voting Results from Special Meeting of Stockholders & Announces December 23rd Investor Webinar
All proposals approved Company not implementing a reverse split at this time Swiss Growth Forum hosting investor webinar Wednesday, December 23rd at 10:30 AM Eastern regarding appearance of ne...
The stock price of Jaguar Health, Inc. (NASDAQ:JAGX) is trading at more than 50% today. This is why it happened.
Jaguar Health (JAGX) is on the move Tuesday as shares of JAGX stock continue to rise and InvestorPlace has what investors need to know. The post Jaguar Health: 10 Things for JAGX Stock Investo...
Jaguar Health (NASDAQ: JAGX) shares are trading higher on Monday after the company announced its plans to develop and commercialize its Crofelemer. Jaguar Health is a commercial-stage pharmace...
Jaguar Health, Inc. (JAGX) CEO Lisa Conte on Q3 2020 Results - Earnings Call Transcript
Jaguar Health CEO And Lead Ethnobotanical Researcher Explain The Decades Of Research That Made It A Leader In Plant-Based Drug Treatment
The following post is sponsored by Jaguar Health, Inc. It is for informational purposes only and not intended to be investing advice. With more than 30 years of ethnobotanical field research a...
Jaguar Health CEO Discusses Upcoming Virtual Event Highlighting Long-Term Treatment Needs Of Cancer Patients
The following post is sponsored by Jaguar Health, Inc. It is for informational purposes only and not intended to be investing advice. Next Tuesday, October 20th, Jaguar Health, Inc. (NASDAQ: J...
If you're wondering how markets are still surging in light of record-breaking coronavirus cases, our deep learning algorithms paired with Artificial Intelligence (“AI”) technology has you cove...
Forget undervalued stocks, play these top-ranked stocks with rising P/E.
Jaguar Health's (JAGX) CEO Lisa Conte on Q1 2020 Results - Earnings Call Transcript
Jaguar Health, Inc. (JAGX) CEO Lisa Conte on Q4 2019 Results - Earnings Call Transcript
Jaguar Health Inc. said Monday evening it has regained compliance with all applicable Nasdaq Stock Market listing standards.
Jaguar Health shares spiked higher Tuesday morning after the company announced its subsidiary, Napo Pharmaceuticals, will receive preclinical services from the federal government to support th...
Jaguar Health, a commercial-stage pharmaceuticals company, focuses on developing gastrointestinal products for human prescription use and animals worldwide. It operates through two reportable segments, Human Health and Animal Health. The company, through its wholly-owned subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals. Its human health product pipelines include crofelemer, which is in Phase III clinical trial for the treatment of cancer therapy-related diarrhea... [Read more...]
|Stock Exchange |
|Ticker Symbol |
In 2019, Jaguar Health's revenue was $5.78 million, an increase of 30.78% compared to the previous year's $4.42 million. Losses were -$38.54 million, 19.9% more than in 2018.
The average 12-month stock price forecast for Jaguar Health is 5.00, which is an increase of 51.52% from the latest price.